Peng Hong-Ye, Lu Chun-Li, Zhao Mo, Huang Xiao-Qiang, Huang Shu-Xia, Zhuo Zi-Wen, Liu Jing, Lu Yan-Ping, Lv Wen-Liang
Department of Infection, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
BMC Gastroenterol. 2025 May 14;25(1):372. doi: 10.1186/s12876-025-03912-0.
Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders.
The National Health and Nutrition Examination Survey for the 2017-2018 cycle was used to screen the participants. Multivariate-adjusted logistic regression models were applied to explore the difference in relative risk analysis between NAFLD/MAFLD/MASLD/MetALD and metabolic disorders.
Among the 1,862 eligible individuals, 358(44.84%) had MASLD, 213(11.44%) had MetALD, 841(45.17%) had MAFLD, and 1,125(60.42%) had NAFLD. Positive associations with the risk of hypertension were discovered for MASLD (OR = 2.892, 95%CI = 2.226-3.756), MetALD (OR = 1.802, 95% CI = 1.355-2.398), MAFLD (OR = 3.455, 95%CI = 2.741-4.354) and NAFLD (OR = 1.983, 95%CI = 1.584-2.484). Positive associations with the risk of T2DM were discovered for MASLD (OR = 6.360, 95%CI = 4.440-9.109), MAFLD (OR = 7.026, 95%CI = 4.893-10.090) and NAFLD (OR = 3.372, 95%CI = 2.511-4.528). We discovered similar results for hyperlipidemia. Compared to mild steatosis, moderate to severe steatosis in patients with MASLD (OR = 3.924, 95%CI = 2.399-6.419), MAFLD (OR = 3.814, 95%CI = 2.367-6.144), NAFLD (OR = 4.910, 95%CI = 2.983-8.080) has a higher risk for T2DM.
The proposed definitions of MASLD and MetALD are valuable and deserve further exploration. Our findings suggest that MAFLD is a more effective indicator for identifying patients at increased risk for metabolic disorders.
我们的目的是比较代谢功能障碍相关脂肪性肝病（MASLD）/代谢性酒精性肝病（MetALD）/代谢相关脂肪性肝病（MAFLD）/非酒精性脂肪性肝病（NAFLD）的临床特征以及代谢紊乱的相对风险分析。
使用2017 - 2018周期的国家健康与营养检查调查来筛选参与者。应用多变量调整逻辑回归模型来探讨NAFLD/MAFLD/MASLD/MetALD与代谢紊乱在相对风险分析方面的差异。
在1862名符合条件的个体中，358人（44.84%）患有MASLD，213人（11.44%）患有MetALD，841人（45.17%）患有MAFLD，1125人（60.42%）患有NAFLD。发现MASLD（OR = 2.892，95%CI = 2.226 - 3.756）、MetALD（OR = 1.802，95%CI = 1.355 - 2.398）、MAFLD（OR = 3.455，95%CI = 2.741 - 4.354）和NAFLD（OR = 1.983，95%CI = 1.584 - 2.484）与高血压风险呈正相关。发现MASLD（OR = 6.360，95%CI = 4.440 - 9.109）、MAFLD（OR = 7.026，95%CI = 4.893 - 10.090）和NAFLD（OR = 3.372，95%CI = 2.511 - 4.528）与2型糖尿病风险呈正相关。对于高脂血症，我们发现了类似的结果。与轻度脂肪变性相比，MASLD（OR = 3.924，95%CI = 2.399 - 6.419）、MAFLD（OR = 3.814，95%CI = 2.367 - 6.144）、NAFLD（OR = 4.910，95%CI = 2.983 - 8.080）患者的中度至重度脂肪变性患2型糖尿病的风险更高。
所提出的MASLD和MetALD定义是有价值的，值得进一步探索。我们的研究结果表明，MAFLD是识别代谢紊乱风险增加患者的更有效指标。
